IMU Biosciences
Develops blood-based immune profiling technology to decode the immune system from a single sample for biotechnology and healthcare applications.
Overview
IMU Biosciences is a London biotech developing technology to decode the immune system using a single blood sample. Its work is positioned for biotechnology and healthcare organizations seeking richer immune-system insight from minimally invasive sampling. The company’s stated differentiator is its single-sample approach to immune profiling, which could support research and clinical applications where immune status is important. IMU Biosciences raised $53 million in an undisclosed round announced in June 2026.
Funding History
London biotech raises $53M to decode the immune system using a single blood sample
Frequently Asked Questions
- How much has IMU Biosciences raised in total?
- IMU Biosciences has raised a total of $53M across 1 funding round.
- Who are IMU Biosciences's investors?
- IMU Biosciences's investors include Undisclosed.
- What does IMU Biosciences do?
- IMU Biosciences is a London biotech developing technology to decode the immune system using a single blood sample. Its work is positioned for biotechnology and healthcare organizations seeking richer immune-system insight from minimally invasive sampling. The company’s stated differentiator is its single-sample approach to immune profiling, which could support research and clinical applications where immune status is important. IMU Biosciences raised $53 million in an undisclosed round announced in June 2026.
- Where is IMU Biosciences headquartered?
- IMU Biosciences is headquartered in London, UK.
Investors
Related Insights
Compare the leading AI-focused VC firms: Andreessen Horowitz, Sequoia Capital, Thrive Capital, and 7 more. Analysis of 150+ AI deals, investment strategies, sector focus, and portfolio performance.
AI startup funding reached $337B across 395 deals in 2026. Complete breakdown of funding stages from pre-seed ($50K-$500K) through IPO, covering valuations, timelines, investor expectations, and how AI funding differs from traditional tech.
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.